These findings establish that IFITM3 upregulates MHC-I expression by promoting NLRC5 expression and facilitating its nuclear trafficking, thereby enhancing antigen presentation and improving immunotherapy efficacy in SCLC. The gene discussed is NLRC5; the disease is small cell lung carcinoma.